Literature DB >> 23895705

Study on the expression levels of CXCR4, CXCL12, CD44, and CD147 and their potential correlation with invasive behaviors of pituitary adenomas.

Bing Xing1, Yan Guo Kong, Yong Yao, Wei Lian, Ren Zhi Wang, Zu Yuan Ren.   

Abstract

OBJECTIVE: To evaluate the factors of CXCR4, CXCL12, CD44, and CD147 as early potential diagnostic biomarkers by determining their expression levels in invasive and non-invasive pituitary adenomas.
METHODS: Fresh pituitary adenoma specimens were collected from 35 pituitary adenoma (21 invasive and 14 non-invasive) patients who underwent surgical treatment in our Neurosurgery Department between January and April of 2009. The expression levels of CXCR4, CXCL12, CD44, and CD147 were evaluated firstly by flow cytometry, fluorescence microscopy in single cell suspensions, and then by immunohistochemical staining of paraffin tissue sections.
RESULTS: Flow cytometric analyses showed that the percentage of CXCR4- and CXCL12-positive cells from invasive pituitary adenomas (IPA) was significantly higher in the single cell suspensions than that from non-invasive pituitary adenomas (nIPA) (P<0.05). Immunohistochemical staining revealed that CXCR4 and CXCL12 staining index scores of the invasive pituitary adenomas were significantly higher than those of the non-invasive pituitary adenomas (P<0.05). In contrast, neither flow cytometry nor immunohistochemical staining demonstrated significant difference between CD44 and CD147 expression levels, respectively.
CONCLUSION: Expression levels of CXCR4 and CXCL12 are correlated with the invasiveness of pituitary adenomas. Therefore, rather than CD44 and CD147, CXCR4 and CXCL12 may potentially serve as biomarkers for early detection of pituitary adenomas.
Copyright © 2013 The Editorial Board of Biomedical and Environmental Sciences. Published by China CDC. All rights reserved.

Entities:  

Keywords:  CXCR4, CXCL12, CD44, and CD147; Flow cytometry; Immunohistochemistry; Invasiveness; Pituitary adenoma

Mesh:

Substances:

Year:  2013        PMID: 23895705     DOI: 10.3967/0895-3988.2013.07.011

Source DB:  PubMed          Journal:  Biomed Environ Sci        ISSN: 0895-3988            Impact factor:   3.118


  10 in total

1.  A retrospective review of 34 cases of pediatric pituitary adenoma.

Authors:  Nannan Zhang; Peizhi Zhou; Yu Meng; Feng Ye; Shu Jiang
Journal:  Childs Nerv Syst       Date:  2017-07-18       Impact factor: 1.475

2.  Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas.

Authors:  Roberto Würth; Federica Barbieri; Alessandra Pattarozzi; Germano Gaudenzi; Federico Gatto; Pietro Fiaschi; Jean-Louis Ravetti; Gianluigi Zona; Antonio Daga; Luca Persani; Diego Ferone; Giovanni Vitale; Tullio Florio
Journal:  Mol Neurobiol       Date:  2016-08-11       Impact factor: 5.590

3.  Up-regulation of the expressions of MiR-149-5p and MiR-99a-3p in exosome inhibits the progress of pituitary adenomas.

Authors:  Peng Zhao; Jianhua Cheng; Bin Li; Ding Nie; Chuzhong Li; Songbai Gui; Hongyun Wang; Yazhuo Zhang
Journal:  Cell Biol Toxicol       Date:  2021-01-05       Impact factor: 6.691

4.  Survivin overexpression is potentially associated with pituitary adenoma invasiveness.

Authors:  Xiangyi Kong; Shun Gong; Lijuan Su; Xinqi Cheng; Honglei Li; Tingting You; Yanguo Kong
Journal:  Oncotarget       Date:  2017-11-10

5.  Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours.

Authors:  Pedro Marques; Sayka Barry; Eivind Carlsen; David Collier; Amy Ronaldson; Sherine Awad; Neil Dorward; Joan Grieve; Nigel Mendoza; Samiul Muquit; Ashley B Grossman; Frances Balkwill; Márta Korbonits
Journal:  Acta Neuropathol Commun       Date:  2019-11-08       Impact factor: 7.801

6.  The role of the tumour microenvironment in the angiogenesis of pituitary tumours.

Authors:  Pedro Marques; Sayka Barry; Eivind Carlsen; David Collier; Amy Ronaldson; Neil Dorward; Joan Grieve; Nigel Mendoza; Ramesh Nair; Samiul Muquit; Ashley B Grossman; Márta Korbonits
Journal:  Endocrine       Date:  2020-09-18       Impact factor: 3.633

7.  SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth via Targeting VEGFA.

Authors:  Xiaoyu Wang; Yuanjian Fang; Yunxiang Zhou; Xiaoming Guo; Ke Xu; Chenguang Li; Jianmin Zhang; Yuan Hong
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-09       Impact factor: 5.555

Review 8.  Pituitary Adenoma and the Chemokine Network: A Systemic View.

Authors:  Fabio Grizzi; Elena Monica Borroni; Alessandro Vacchini; Dorina Qehajaj; Manuela Liguori; Sanja Stifter; Maurizio Chiriva-Internati; Antonio Di Ieva
Journal:  Front Endocrinol (Lausanne)       Date:  2015-09-11       Impact factor: 5.555

Review 9.  Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System.

Authors:  Federica Barbieri; Stefano Thellung; Roberto Würth; Federico Gatto; Alessandro Corsaro; Valentina Villa; Mario Nizzari; Manuela Albertelli; Diego Ferone; Tullio Florio
Journal:  Int J Endocrinol       Date:  2014-11-17       Impact factor: 3.257

Review 10.  Experimental Evidence and Clinical Implications of Pituitary Adenoma Stem Cells.

Authors:  Roberto Würth; Stefano Thellung; Alessandro Corsaro; Federica Barbieri; Tullio Florio
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-20       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.